What is Optina Diagnostics?
Optina Diagnostics, headquartered in Montreal, is at the forefront of transforming brain health assessment. The company is dedicated to challenging conventional approaches by offering an accurate, user-friendly, and non-invasive optical testing solution designed to identify age-related memory loss causes. This innovative diagnostic tool aims to empower millions by providing clear insights into systemic diseases, with an initial application focused on the early diagnosis of Alzheimer's disease. Their commitment to innovation positions them as a key player in the burgeoning field of neurodegenerative disease diagnostics.
How much funding has Optina Diagnostics raised?
Optina Diagnostics has raised a total of $22.1M across 2 funding rounds:
Series A
$20M
Unspecified
$2.1M
Series A (2021): $20M with participation from Desjardins Capital, Boehringer Ingelheim Venture Fund, DigitalDx Ventures, and Hike Ventures
Unspecified (2022): $2.1M led by Alzheimer's Drug Discovery Foundation
Key Investors in Optina Diagnostics
Alzheimer's Drug Discovery Foundation
The Alzheimer's Drug Discovery Foundation is a not-for-profit organization dedicated to accelerating the development of drugs for Alzheimer's disease through innovative research funding and partnerships. They focus on venture philanthropy, investing in promising research projects and using returns to further their mission.
Desjardins Capital
Desjardins Capital is an investment fund focused on investing in small and medium-sized enterprises in Quebec, providing financial backing to support their growth and development.
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science aimed at redefining care standards and developing new medicines for patients, focusing on first-in-class, disease-modifying therapeutics across various modalities.
What's next for Optina Diagnostics?
With this significant enterprise-level funding, Optina Diagnostics is poised for accelerated growth and market expansion. The strategic nature of the recent investment suggests a focus on scaling operations, enhancing research and development capabilities, and forging key partnerships within the healthcare ecosystem. This capital infusion will likely enable Optina to further refine its diagnostic technology, broaden its clinical applications, and solidify its position as a leader in non-invasive brain health assessment, ultimately aiming to improve patient outcomes through earlier and more accurate diagnoses.
See full Optina Diagnostics company page
